News|Articles|August 24, 2023

Indegene Launches Invisage, a New Omnichannel Sales and Marketing Platform

Program designed to aid life science organizations in improving go-to-market strategy.

Indegene has officially launched Invisage, its new sales and marketing program. Aimed at helping life science companies optimize their go-to-market models, the technology reportedly delivers personalized outcomes to healthcare professionals (HCPs) by leveraging data from over two million HCPs with over 200 million interactions.

Indegene describes Invisage as an integrated hybrid omnichannel platform that combines data, AI-driven scientific modeling, and strategic insights to deploy digital campaigns and partner digital channels with a sales force to expand HCP reach and optimize interactions.

“We are excited to introduce Invisage to the market and enable life sciences companies to effectively reach HCPs, powered by Indegene’s AI-driven platform and our team of experts,” said Nancy Phelan, SVP, omnichannel activation, Indegene. “Invisage paves the way for companies to seamlessly transition to and sustain a hybrid model, knowing that this modern approach can provide HCPs the personalized information they need to deliver improved patient outcomes.”

Reference: Indegene launches Invisage, an AI-enabled hybrid omnichannel sales and marketing platform to improve HCP impact for life sciences companies. GlobNewswire. August 22, 2023. Accessed August 23, 2023. https://www.globenewswire.com/news-release/2023/08/22/2729333/0/en/Indegene-launches-Invisage-an-AI-enabled-hybrid-omnichannel-sales-and-marketing-platform-to-improve-HCP-impact-for-life-sciences-companies.html


Related to this article

CVS Pharmacy Sign at Storefront Entrance | © Mark Roger Bailey - stock.adobe.com 557616813
In this week’s Pharma Pulse, CVS Health plans to separate into two public companies, Bayer weighs what MFN pricing could mean for its launch strategies and an ACTO survey finds most life sciences leaders see no clear industry standard for responsible AI.